Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

2482.425 - 2512.318 Dr. Bogdana Schmidt

And because this was phase two, we were looking at pathologic complete response patients. as the primary endpoint in these patients. And it was really, you know, I think, striking. CR in that combo arm, TAR200 plus citralumab, was 42%, which is sort of what we saw in the neoadjuvant chemo trials. Nothing went above 30%, right? So there's some neoadjuvant immunotherapy trials, but